Experience of combined use of non-freon ultra-fine dispersed inhaler beclomethasone and formoterol in moderate bronchial asthma children

Abstract

Open non-comparative 3-month study of efficacy of combined therapy with beclomethasone (Beclason ECO Easy Breathe) and formoterol (Foradil) was performed in children 6 to 11 years old with moderate bronchial asthma. The study involved 35 patients (the average age was 8.64 ± 0.65 yrs), 69 % were boys. The length of the disease was 2 to 10 yrs (6.01 ± 0.83 yrs). All the patients were given Beclason ECO Easy Breathe 200 meg and Foradil 9 meg twice a day. We evaluated inhalation technique, clinical and functional dynamics, possibilities of achieving the full asthma control, need in short-acting β₁-agonists, tolerability and safety of the therapy. No one patient experienced technique problems when using Beclason ECO Easy Breathe. By the 8-th week of the treatment asthma symptoms disappeared in all the patients, breathing rate and lung auscultation became normal. Significant improvement in lung function was noted by the 12-th week of the therapy. The FEV₁ growth under the bronchodilating test diminished indicating more bronchial stability. Peak expiratory flow rate increased even in children with initial normal parameters. The need in short-acting β₂-agonists reduced from 1,9 ± 0,4 to 0,6 ± 0,2 doses daily. The treatment was well tolerated.

Thus, the combination of Beclason ECO Easy Breathe and Foradil in moderate asthma children results in achieving the full asthma control, clinical stability, elimination of the asthma signs, improvement in lung function.